Clinical Trial Update: Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CC-292 added to methotrexate versus placebo in active rheumatoid arthritis has completed, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CC-292
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Celgene | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED